

## **SEARCH STRATEGY**

### **Pub Med:**

("Somalia"[Title/Abstract] OR "Somali"[Title/Abstract]) AND ("hepatitis b virus"[Title/Abstract] OR "HBV"[Title/Abstract] OR "hepatitis b"[Title/Abstract]) AND ("prevalence"[Title/Abstract] OR "occurrence"[Title/Abstract] OR "distribution"[Title/Abstract]).

### **Scopus:**

((Hepatitis B) OR (Hepatitis B virus) OR (HBV)) AND (Somalia OR Somali)

### **Science Direct:**

Title: Hepatitis B virus AND Somalia OR Somali

### **Google Scholar:**

hepatitis B virus "Somalia" OR "Somali"



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3-4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5-6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5-6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5-6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5-6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5-6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7-11
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	12
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	12
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	12
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12-16
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19-21
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	20-21
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	19-21
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	21

**QUALITY OF INCLUDED STUDIES BY JBI CRITICAL APPRAISAL CHECKLIST FOR STUDIES  
REPORTING PREVALENCE DATA**

S/N	Name of authors and year of publication		JBI checklist*									Total	
			1	2	3	4	5	6	7	8	9		
1	Padovese et al	2014											
2	Kadle et al	2012	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
3	Shire et al	2012	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
4	Khadjio	2011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	16
5	Aweis et al	2001	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
6	Nur et al	2000	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
7	Faustini et al	1994	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
8	Bile et al (a)	1992	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
9	Mohamud et al	1992	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
10	Bile et al	1991	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	16
11	Aceti et al	1989	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
12	Bile et al (b)	1991	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
13	Aceti et al	1991	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	16
14	Jama et al	1987	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	16
15	Bile et al (c)	1987	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
16	Sebastiani et al	1985	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
17	Nuti et al (a)	1979	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
18	Nuti et al (b)	1979	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	16
19	Nuti et al (c)	1978	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
20	Nuti et al (d)	1979	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
21	Delia et al	1977	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
22	Sebastiani et al	1984	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18
23	Eneh et al	2021	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	16
24	Mohamed et al	2021	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	18

**JBI CHECKLIST\*** 1. Appropriate sampling frame to address target population, 2. Appropriate sampling way of study participants, 3. Adequate sample size, 4. Detail description of study participants and settings, 5. Data analysis with sufficient coverage of identified sample, 6. Use of valid methods to identify the condition, 7. Standard, reliable way of measurement of condition for all participants, 8. Availability of appropriate statistical analysis, 9. Adequate response rate and management of low response rate.

**Scores are coded as Yes=1 and No=0.**